Amphastar Pharmaceuticals, Inc.

Total Valuation

Amphastar Pharmaceuticals, Inc. carries a market capitalization of 798.96M, placing it among publicly traded companies globally. Its enterprise value stands at 1.30B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Amphastar Pharmaceuticals, Inc. currently has 44.64M shares outstanding.

Valuation Ratios

Amphastar Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 11.41. The price-to-sales ratio is 1.26, and the price-to-book ratio stands at 1.34.

Enterprise Valuation

On an enterprise value basis, Amphastar Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 7.17 and an EV/FCF ratio of 5.84. The EV/Sales ratio of 1.80 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 11.13 provides insight into valuation relative to core operating earnings.

Financial Position

Amphastar Pharmaceuticals, Inc. maintains a current ratio of 3.85, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 88.75, indicating elevated leverage, while an interest coverage ratio of 7.04 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Amphastar Pharmaceuticals, Inc. posts a return on equity of 12.50 and a return on invested capital of 6.25.

Taxes

Over the trailing twelve months, Amphastar Pharmaceuticals, Inc. has paid 23.59M in income taxes, reflecting an effective tax rate of 22.94.

Stock Price Statistics

Amphastar Pharmaceuticals, Inc.'s stock has declined approximately -30.33449% over the past 52 weeks. The 50-day moving average sits at 20.17, while the 200-day moving average is 24.67.

Income Statement

Over the trailing twelve months, Amphastar Pharmaceuticals, Inc. generated 720.53M in revenue and converted that into 79.23M in net income, yielding earnings per share of 1.67. EBITDA reached 181.23M, while operating income came in at 116.74M.

Balance Sheet

Amphastar Pharmaceuticals, Inc. holds 291.95M in cash and equivalents against 686.38M in total debt, resulting in a net debt position of 440.53M. Total book value stands at 673.31M, with working capital of 469.21M providing operational flexibility.

Cash Flow

Amphastar Pharmaceuticals, Inc. produced 168.88M in operating cash flow over the past twelve months. After subtracting -33.69M in capital expenditures, free cash flow totaled 135.19M - equivalent to 2.93 per share.

Margins

Amphastar Pharmaceuticals, Inc. operates with a gross margin of 47.34, reflecting its pricing power and cost economics. The operating margin of 16.20 and net profit margin of 11.00 provide insight into operational efficiency.

Dividends & Yields

Scores

Amphastar Pharmaceuticals, Inc. posts an Altman Z-Score of 3.02, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.